nystatin-a1 and Erythema

Extended use of antimycotics in oral candidiasis therapy gives rise to problems related to fungal drug resistance. The aim of this pilot study was to investigate the efficacy of tissue tolerable plasma (TTP) in denture stomatitis patients. It was hypothesised that (I): erythema and (IIa): complaint remission would be accelerated and (IIb): colony forming unit (CFU) reduction would be improved. The halves of the upper jaws of eight patients were randomly assigned to control (nystatin, chlorhexidine and placebo treatment) and test sides (nystatin, chlorhexidine and TTP administered six times each 7 days). The patients and the investigators, who were different from the therapists, were both blinded. Compared to the control sides, the erythema surface was reduced significantly more extensively on the test sides between 2 and 6 weeks of antifungal therapy (P ≤ 0.05). Visual analogue scale values and the frequency of moderate or heavy growth of Candida post-treatment did not differ significantly between both sides (P > 0.05). The primary hypothesis was confirmed, which may be interpreted as an accelerated remission. As drug therapy is usually limited to the time in which signs of infection are present, TTP might help reducing antifungal use. Even though the secondary hypotheses were not confirmed, persistence of Candida might be only colonisation.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Candida; Candidiasis, Oral; Chlorhexidine; Dentures; Double-Blind Method; Drug Resistance, Fungal; Erythema; Female; Humans; Male; Middle Aged; Mouth Mucosa; Mouthwashes; Nystatin; Pilot Projects; Plasma Gases; Young Adult

Denture stomatitis (DS) is the most common form of chronic oral candidiasis. The standard treatment for DS is nystatin, which is accompanied with complications such as a bitter taste. The aim of this study was to compare the effect of garlic with nystatin in DS.. This randomised clinical trial study was performed on 40 patients with DS. After obtaining written consent, patients were divided into two groups while members of each group were given either nystatin or garlic extract for 4 weeks. The length and width of erythema area was measured at the end of the first, second, third, and the fourth weeks using a calliper. Data were analysed by SPSS and statistical tests including variance analysis with anova repeated measures, chi-square, and least square differences.. The changes in the length and width of erythema at different times according to the type of treatment were found to be significant while an accelerated recovery was demonstrated for nystatin (p < 0.001). Both regimens resulted in significant recovery (p < 0.0001). Greater satisfaction with the use of garlic rather than nystatin was mentioned (p < 0.0001).. Considering the efficacy of garlic and lack of side effects for this compound and also regarding the nystatin-associated complications, garlic extract can be introduced as a substitution for standard treatment in DS.

Topics: Aged; Antifungal Agents; Candidiasis, Oral; Diarrhea; Double-Blind Method; Erythema; Female; Garlic; Humans; Male; Mouthwashes; Nausea; Nystatin; Patient Satisfaction; Phytotherapy; Plant Extracts; Stomatitis, Denture; Taste Disorders

The efficacy of oral fluconazole versus nystatin was evaluated as a treatment modality for oral candidosis. Of the included patients (n = 60), two-thirds presented with an erythematous candidosis, and the others showed clinical signs compatible with a pseudomembranous candidosis. Predisposing factors were xerostomia (n = 18), HIV (n = 5), immunosuppression in conjunction with organ transplantation (n = 10), and wearing of dentures (n = 14). For the remaining patients no specific predisposing factors were found. One patient who was treated with nystatin was excluded owing to nausea that was related to the antifungal treatment. After 7 days of treatment with fluconazole (50 mg/day), the affected oral mucosa, assessed by the investigator, was cured or showed considerable improvement in 87% of the patients (n = 30). The corresponding figure for the nystatin group (n = 30), rinsing with 1 mL 4 times a day for 21 days, was 80%. Following treatment with fluconazole, 20 of 22 patients with symptoms at the start (91%) reported improvement. The comparable figures for the nystatin group were 10 of 12 patients (83%). Half of the patients in the nystatin group reported inconvenience from taking the medication (mean value = 25.9) compared with 23% of the patients in the fluconazole group (mean value = 6.6). Eight patients in the fluconazole group and 12 patients in the nystatin group exhibited a relapse within 6 months. These differences were not found to be statistically significant. The patients in the fluconazole group reported less inconvenience from taking the medication, a finding that may have clinical implications for compliance.

Topics: Administration, Oral; Adult; Aged; Antifungal Agents; Candidiasis, Oral; Capsules; Dentures; Erythema; Female; Fluconazole; Follow-Up Studies; HIV Infections; Humans; Immunosuppression Therapy; Male; Middle Aged; Mouth Mucosa; Mouthwashes; Nystatin; Organ Transplantation; Patient Compliance; Patient Satisfaction; Recurrence; Risk Factors; Xerostomia

Topics: Administration, Oral; Amoxicillin; Anti-Bacterial Agents; Antifungal Agents; Drug Eruptions; Drug Hypersensitivity; Erythema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mycoses; Nystatin; Opportunistic Infections; Patch Tests; Time Factors; Tooth Diseases; Withholding Treatment

This study represents a 1-year surveillance period using our epidemiology-based principles published and successfully followed since 1979: weekly culture for yeasts of oral and anal swabs, treatment with oral nystatin of all colonized newborns, and good hygiene/handwashing. Colonization was demonstrated in 23 out of 791 newborns admitted from October 1998 to September 1999. Twenty-two strains of Candida were identified: 16 C. albicans, 2 C. parapsilosis, 3 C. glabrata, and 1 C. tropicalis. Symptoms were erythema of the buttocks in 6 colonized newborns. No other culture positive for Candida could be found. Previous contamination was the main source (previous stay in an intensive care unit, rarely maternal origin). Contamination in the unit was unlikely. Eradication of Candida could be observed within 1 week. These good results, controversial in the literature, were obtained following epidemiological conclusions and support our guidelines.

Topics: Buttocks; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Candidiasis; Cross Infection; Erythema; Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Intensive Care, Neonatal; Male; Miconazole; Nystatin

A 64-year-old woman had severe vulvovaginitis develop while she was receiving intravaginal nystatin therapy for Candida glabrata infection. Mucocutaneous adverse effects have rarely been reported with nystatin despite long years of use. This complication should be included in the differential diagnosis of clinical failure of intravaginal nystatin therapy.

Topics: Administration, Intravaginal; Anti-Inflammatory Agents; Antifungal Agents; Betamethasone; Candidiasis; Edema; Erythema; Female; Humans; Hydrocortisone; Middle Aged; Nystatin; Vulvovaginitis

Topics: Amphotericin B; Antifungal Agents; Candidiasis; Erythema; Female; Humans; Intestinal Diseases; Male; Middle Aged; Nystatin

Topics: Aged; Blood Protein Disorders; Cryoglobulins; Dexamethasone; Erythema; Female; Fibrinogen; Glucocorticoids; Humans; Nystatin; Oxacillin; Purpura; Skin Diseases; Triamcinolone

Topics: Candida albicans; Candidiasis; Drug Therapy; Erythema; Humans; Hypersensitivity; Hypersensitivity, Delayed; Nystatin; Skin Diseases, Genetic